Exagen Inc. (XGN)

Market Cap	73.84M +1.9%
Revenue (ttm)	66.58M +19.7%
Net Income	-19.95M
EPS	-0.93
Shares Out	24.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	91,951
Open	3.080
Previous Close	3.080
Day's Range	3.065 - 3.190
52-Week Range	2.590 - 12.230
Beta	1.94
Analysts	Strong Buy
Price Target	9.14 (+197.72%)
Earnings Date	May 4, 2026

About XGN

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company’s lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CT...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Sep 19, 2019
• Employees: 220
• Stock Exchange: NASDAQ
• Ticker Symbol: XGN
• Website: https://www.exagen.com

Financial Performance

In 2025, Exagen's revenue was $66.58 million, an increase of 19.65% compared to the previous year's $55.64 million. Losses were -$19.95 million, 32.0% more than in 2024.

Analyst Summary

According to 7 analysts, the average rating for XGN stock is "Strong Buy." The 12-month stock price target is $9.14, which is an increase of 197.72% from the latest price.

Price Target

$9.14

(197.72% upside)

Analyst Consensus: Strong Buy